Inquis Medical
has announced the successful closure of its US$40 million series B financing round. This round was led by Marshall Wace, a globally recognised investment firm, with participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.
Inquis Medical is a clinical-stage medical device company dedicated to bringing next-generation thrombectomy systems to market. Its flagship product, the Aventus thrombectomy system, features proprietary tissue-sensing technology that provides operators with real-time information on the tissue composition in contact with the device. This innovative system offers enhanced precision and control during procedures, pushing the boundaries of what current thrombectomy systems can achieve.
Earlier this year, Inquis received US Food and Drug Administration (FDA) 510(k) clearance for its Aventus system, as well as its blood return system for peripheral indications, and is nearing completion of enrolment in an FDA investigational device exemption (IDE) pivotal clinical study targeting pulmonary embolism (PE) patients.
“We are thrilled to have successfully secured our series B funding. This is a strong validation of the confidence investors have in our mission and the potential impact of our innovations,” said Vahid Saadat, co-chief executive officer (CEO) and co-founder of Inquis Medical.
“This substantial investment from Marshall Wace, along with our existing investors, underscores a strong belief in both our technology and our team,” said Mojgan Saadat, co-CEO and co-founder. “We are excited for the next phase of the company and look forward to enhancing patient care by empowering physicians with our unique technology.”
In connection with the series B financing, Andrew D Goldberg, a portfolio manager at Marshall Wace, has joined Inquis Medical’s board of directors.
This capital injection represents a significant milestone in Inquis Medical’s rapid development and will enable the company to complete its pivotal IDE trial, prepare for the commercial launch of the Aventus system in 2025, and continue to advance its proprietary tissue-sensing platform.
In the USA, up to 900,000 individuals are affected by venous thromboembolism (VTE) each year, with over 50% of deep vein thrombosis cases leading to PE, which is the third leading cause of cardiovascular death. Current lytic-free aspiration thrombectomy procedures are often limited by significant blood loss and procedural inefficiencies, making Inquis Medical’s innovations a promising advancement in the field.
